0001209191-20-051062.txt : 20200917
0001209191-20-051062.hdr.sgml : 20200917
20200917203405
ACCESSION NUMBER: 0001209191-20-051062
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20200917
FILED AS OF DATE: 20200917
DATE AS OF CHANGE: 20200917
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yamada Tadataka
CENTRAL INDEX KEY: 0001402530
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39503
FILM NUMBER: 201182479
MAIL ADDRESS:
STREET 1: COVIDIEN LTD.
STREET 2: 15 HAMPSHIRE STREET
CITY: MANSFIELD
STATE: MA
ZIP: 02048
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Athira Pharma, Inc.
CENTRAL INDEX KEY: 0001620463
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4000 MASON ROAD, SUITE 300
STREET 2: BOX 352141
CITY: SEATTLE
STATE: WA
ZIP: 981952141
BUSINESS PHONE: 5095927191
MAIL ADDRESS:
STREET 1: 4000 MASON ROAD, SUITE 300
STREET 2: BOX 352141
CITY: SEATTLE
STATE: WA
ZIP: 981952141
FORMER COMPANY:
FORMER CONFORMED NAME: M3 Biotechnology, Inc.
DATE OF NAME CHANGE: 20140924
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-09-17
0
0001620463
Athira Pharma, Inc.
ATHA
0001402530
Yamada Tadataka
C/O ATHIRA PHARMA, INC.
4000 MASON ROAD, SUITE 300
SEATTLE
WA
98195
1
0
0
0
Stock Option (Right to Buy)
1.35
2028-12-17
Common Stock
12610
D
Stock Option (Right to Buy)
1.35
2028-12-17
Common Stock
12610
D
Stock Option (Right to Buy)
1.35
2029-06-25
Common Stock
25220
D
Stock Option (Right to Buy)
1.35
2030-01-28
Common Stock
31525
D
Stock Option (Right to Buy)
17.00
2030-09-16
Common Stock
27742
D
Reflects a 7.9302-for-1 reverse stock split of the outstanding shares of the Issuer effected September 11, 2020.
The shares subject to the option fully vested on June 19, 2020.
One-half of the shares subject to the option vested on January 1, 2020 and one-half of the shares subject to the option vest on each year thereafter.
One-third of the shares subject to the option vested on June 26, 2020 and one-thirty-sixth of the shares subject to the option will vest on each month thereafter.
One-third of the shares subject to the option will vest on December 13, 2020 and one-thirty-sixth of the shares subject to the option will vest on each month thereafter.
One-thirty-sixth of the shares subject to the option will vest on October 17, 2020 and one-thirty-sixth of the shares subject to the option will vest each month thereafter.
Glenna Mileson, Attorney in fact for Tadataka Yamada
2020-09-17
EX-24.3_937723
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
The undersigned, as a Section 16 reporting person of Athira Pharma, Inc. (the
Company), hereby constitutes and appoints Glenna Mileson, Barbara Mery and each
of the responsible attorneys and paralegals of Wilson Sonsini Goodrich & Rosati,
Professional Corporation, the undersigneds true and lawful attorney-in-fact to:
1. complete and execute Forms ID, 3,4 and 5 and other forms and all amendments
thereto as such attorney-in-fact shall in his or her discretion determine to be
required or advisable pursuant to Section 16 of the Securities Exchange Act of
1934 (as amended) and the rules and regulations promulgated thereunder, or any
successor laws and regulations, as a consequence of the undersigneds ownership,
acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the Securities and
Exchange Commission, any securities exchange or national association, the
Company and such other person or agency as the attorney-in-fact shall deem
appropriate.
The undersigned hereby ratifies and confirms all that said attorneys-in-fact and
agents shall do or cause to be done by virtue hereof. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigneds responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934 (as amended).
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to
the undersigneds holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the Company and the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of August 28, 2020. .
Signature: /s/ Tadataka Yamada
Tadataka Yamada